ALLO - Allogene Therapeutics Inc Stock Price, Fair Value and News

2.97USD+0.07 (+2.41%)Market Closed

Market Summary

USD2.97+0.07

Market Closed

2.41%

ALLO Stock Price

View Fullscreen

ALLO RSI Chart

ALLO Valuation

Market Cap

507.4M

Price/Earnings (Trailing)

-1.74

Price/Sales (Trailing)

5.8K

EV/EBITDA

-1.79

Price/Free Cashflow

-2.23

ALLO Price/Sales (Trailing)

ALLO Profitability

EBT Margin

-295408.05%

Return on Equity

-63.35%

Return on Assets

-49.85%

Free Cashflow Yield

-44.83%

ALLO Fundamentals

ALLO Revenue

Revenue (TTM)

87.0K

Rev. Growth (Yr)

-26.67%

Rev. Growth (Qtr)

4.76%

ALLO Earnings

Earnings (TTM)

-292.3M

Earnings Growth (Yr)

34.98%

Earnings Growth (Qtr)

24.22%

Breaking Down ALLO Revenue

Last 7 days

-3.6%

Last 30 days

-23.7%

Last 90 days

-37.1%

Trailing 12 Months

-52.4%

How does ALLO drawdown profile look like?

ALLO Financial Health

Current Ratio

12.8

ALLO Investor Care

Shares Dilution (1Y)

17.15%

Diluted EPS (TTM)

-1.79

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	87.0K	0	0	0
2023	147.0K	105.0K	100.0K	95.0K
2022	85.6M	57.1M	28.6M	156.0K
2021	0	0	0	114.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Allogene Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 22, 2024	moore timothy l.	sold (taxes)	-60,188	3.4671	-17,360	chief technical officer
Mar 14, 2024	chang david d	sold (taxes)	-231,192	4.33	-53,393	president and ceo
Jan 30, 2024	parker geoffrey m.	bought	683	3.595	190	chief financial officer
Jan 25, 2024	chang david d	acquired	-	-	317,800	president and ceo
Jan 25, 2024	parker geoffrey m.	acquired	-	-	29,400	chief financial officer
Jan 25, 2024	roberts zachary	acquired	-	-	140,000	evp of r&d
Jan 25, 2024	moore timothy l.	acquired	-	-	96,600	chief technical officer
Jan 25, 2024	belldegrun arie	acquired	-	-	211,973	-
Jan 25, 2024	douglas earl martin	acquired	-	-	41,800	svp, general counsel
Jan 22, 2024	roberts zachary	sold (taxes)	-78,375	3.1744	-24,690	evp of r&d

Which funds bought or sold ALLO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 13, 2024	Continuum Advisory, LLC	new	-	1,573	1,573	-%
May 13, 2024	Ameritas Investment Partners, Inc.	unchanged	-	10,211	36,225	-%
May 13, 2024	Nuveen Asset Management, LLC	reduced	-15.47	203,319	1,351,080	-%
May 13, 2024	XTX Topco Ltd	added	1.07	46,281	159,870	0.02%
May 13, 2024	UBS Group AG	added	186	1,739,190	2,320,830	-%
May 13, 2024	CANADA LIFE ASSURANCE Co	added	85.13	48,000	79,000	-%
May 13, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.85	57,390	208,154	-%
May 13, 2024	Balyasny Asset Management L.P.	added	35.52	44,794	95,287	-%
May 13, 2024	Creative Planning	added	10.64	49,134	140,009	-%
May 13, 2024	Rafferty Asset Management, LLC	added	332	3,693,330	4,428,440	0.02%

Are Funds Buying or Selling ALLO?

Are funds buying ALLO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ALLO

No. of Funds

Unveiling Allogene Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	chang david d	5.8%	9,964,347	SC 13G/A
Feb 14, 2024	belldegrun arie	5.8%	9,895,903	SC 13G/A
Feb 13, 2024	vanguard group inc	5.37%	9,030,825	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 29, 2024	blackrock inc.	5.9%	10,001,804	SC 13G/A
Jan 23, 2024	state street corp	1.44%	2,427,284	SC 13G/A
Oct 25, 2023	pfizer inc	13.14%	22,032,040	SC 13D/A
Jul 10, 2023	fmr llc	-	0	SC 13G
Feb 13, 2023	chang david d	5.7%	8,427,632	SC 13G
Feb 13, 2023	belldegrun arie	6.1%	8,858,861	SC 13G/A

Recent SEC filings of Allogene Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 13, 2024	10-Q	Quarterly Report
May 13, 2024	8-K	Current Report
Apr 25, 2024	EFFECT	EFFECT
Apr 24, 2024	4	Insider Trading
Apr 23, 2024	ARS	ARS
Apr 23, 2024	DEF 14A	DEF 14A
Apr 23, 2024	DEFA14A	DEFA14A
Apr 22, 2024	144	Notice of Insider Sale Intent
Mar 18, 2024	4	Insider Trading
Mar 14, 2024	10-K	Annual Report

Peers (Alternatives to Allogene Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	49.2B	6.8B	19.54%	-2.80%	-8.24	7.18	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.7B	2.0B	0.98%	-26.98%	-56.37	9.34	75.20%	68.82%
BMRN	15.1B	2.5B	-12.72%	-14.31%	73.61	6.12	13.74%	186.89%
INCY	12.8B	3.8B	6.98%	-11.75%	17.19	3.4	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.91	4.73	60.38%	-34.49%
NVAX	1.9B	996.6M	206.31%	55.15%	-4.75	1.9	-26.66%	65.49%
CRBP	456.3M	881.7K	5.07%	336.18%	-13.52	481.06	-77.61%	33.36%
INO	297.2M	4.9M	3.08%	29.79%	-2.38	61.07	-54.97%	48.23%
IBIO	16.2M	2.1M	-10.40%	79.21%	-0.7	7.61	-13.45%	69.54%

Allogene Therapeutics Inc News

Latest updates

Allogene Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)													(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1
Revenue	4.8%	22.00	21.00	22.00	22.00	30.00	26.00	27.00	64.00	37,858	75,651	49.00	44.00	38,345
Operating Expenses	-18.3%	69,526	85,130	63,018	80,562	99,122	96,421	82,538	76,680	80,053	73,944	77,719	71,073	71,546
S&GA Expenses	-100.0%	-	17,224	17,041	18,524	18,884	21,002	18,897	19,509	19,897	19,961	18,999	18,783	16,363
R&D Expenses	-4.4%	52,259	54,661	45,977	62,038	80,238	75,419	63,641	57,171	60,156	53,983	58,720	52,290	55,183
EBITDA Margin	-9.2%	-2.79	-2.56	-2.43	-2.31	-1.65	-1.56	-8.43*	-4.26*	-2.86*	-2.16*	-	-	-
EBT Margin	-9.2%	-2.95	-2.71	-2.57	-2.45	-1.75	-1.65	-8.97*	-4.50*	-3.00*	-2.25*	-	-	-
Net Income	24.2%	-65,000	-85,778	-62,287	-79,232	-99,968	-97,275	-84,242	-80,290	-78,607	86.00	-78,186	-70,936	-33,015
Net Income Margin	2.5%	-3.36	-3.44	-3.39	-3.44	-2.46	-2.18	-8.49*	-4.15*	-2.66*	-1.60*	-	-	-
Free Cashflow	-3.7%	-55,907	-53,888	-55,542	-62,145	-67,674	-63,788	-47,878	-43,905	-70,139	-46,172	-52,225	-52,072	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-8.8%	586	643	713	773	750	822	894	956	978	1,051	1,079	1,127	1,179	1,228	1,223	1,259	689	718	696	734	749
Current Assets	-13.9%	395	459	473	502	481	529	569	513	470	471	503	602	716	845	854	910	504	545	510	512	477
Cash Equivalents	-26.2%	61.00	83.00	69.00	155	110	62.00	74.00	96.00	85.00	173	199	233	246	193	168	285	140	179	165	117	97.00
Net PPE	-3.6%	96.00	99.00	103	106	110	113	114	117	120	123	126	125	123	119	103	85.00	66.00	56.00	46.00	36.00	20.00
Liabilities	-4.3%	125	131	133	152	158	155	151	149	113	126	109	103	109	148	104	95.00	82.00	89.00	76.00	78.00	68.00
Current Liabilities	-16.7%	31.00	37.00	37.00	55.00	59.00	54.00	48.00	44.00	37.00	48.00	53.00	46.00	55.00	94.00	50.00	41.00	27.00	33.00	33.00	38.00	27.00
Shareholder's Equity	-9.9%	461	512	581	621	592	667	743	806	865	925	970	1,024	1,070	1,013	1,119	1,163	607	629	620	656	681
Retained Earnings	-4.2%	-1,627	-1,562	-1,476	-1,414	-1,334	-1,234	-1,137	-1,053	-973	-894	-828	-750	-679	-712	-577	-511	-450	-396	-335	-284	-243
Additional Paid-In Capital	0.7%	2,089	2,075	2,059	2,039	1,933	1,912	1,894	1,871	1,848	1,822	1,799	1,774	1,749	1,726	1,695	1,673	1,055	1,024	953	938	923
Shares Outstanding	1.1%	170	169	168	167	146	144	144	144	144	143	137	134	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	557	-	-	-	1,009	-	-	-	2,254	-	-	-	3,509	-	-	-	1,601	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-4.1%	-55,899	-53,707	-55,530	-61,857	-66,639	-62,096	-47,655	-42,531	-68,237	-45,436	-48,878	-41,170	-49,328	-9,975	-37,588	-26,721	-40,809	-50,267	-31,935	-24,892	-30,256
Share Based Compensation	-21.7%	11,924	15,233	15,354	16,594	18,770	17,246	21,148	22,891	22,315	22,036	20,856	21,134	16,792	16,453	17,823	16,770	14,215	13,874	12,835	11,487	7,867
Cashflow From Investing	-67.2%	22,133	67,461	-34,267	17,160	112,935	49,597	24,905	54,034	-22,377	29,250	13,013	24,594	96,798	22,210	-83,355	-428,971	-15,007	7,929	78,775	44,492	32,888
Cashflow From Financing	964.5%	1,650	155	4,285	89,524	1,731	46.00	1,066	24.00	1,814	322	2,383	3,214	6,044	12,978	3,852	600,175	16,586	56,474	1,566	236	684

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ALLO Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues
Collaboration revenue - related party	$ 22	$ 30
Operating expenses:
Research and development	52,259	80,238
General and administrative	17,267	18,884
Total operating expenses	69,526	99,122
Loss from operations	(69,504)	(99,092)
Other income (expense), net:
Interest and other income, net	5,433	2,059
Other expenses	(929)	(2,935)
Total other income (expense), net	4,504	(876)
Net loss	(65,000)	(99,968)
Other comprehensive loss:
Net unrealized gain on available-for-sale investments	28	3,992
Net comprehensive loss	$ (64,972)	$ (95,976)
Net loss per share, basic (in dollars per share)	$ (0.38)	$ (0.69)
Net loss per share, diluted (in dollars per share)	$ (0.38)	$ (0.69)
Weighted-average number of shares used in computing net loss per share, basic (in shares)	169,128,362	144,563,829
Weighted-average number of shares used in computing net loss per share, diluted (in shares)	169,128,362	144,563,829

ALLO Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 51,039	$ 83,155
Short-term investments	333,821	365,542
Prepaid expenses and other current assets	10,504	10,418
Total current assets	395,364	459,115
Long-term investments	12,405	0
Operating lease right-of-use asset	64,483	63,703
Property and equipment, net	95,931	99,478
Restricted cash	10,292	10,292
Other long-term assets	5,159	6,604
Equity method investments	2,716	3,645
Total assets	586,350	642,837
Current liabilities:
Accounts payable	5,779	5,897
Accrued and other current liabilities	25,029	31,096
Deferred revenue	86	86
Total current liabilities	30,894	37,079
Lease liability, noncurrent	88,916	88,346
Other long-term liabilities	5,173	5,179
Total liabilities	124,983	130,604
Commitments and Contingencies (Notes 6 and 7)
Stockholders’ equity:
Preferred stock, $0.001 par value: 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023; no shares were issued and outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.001 par value: 400,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 170,452,967 and 168,642,238 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	170	169
Additional paid-in capital	2,089,357	2,075,252
Accumulated deficit	(1,627,233)	(1,562,233)
Accumulated other comprehensive loss	(927)	(955)
Total stockholders’ equity	461,367	512,233
Total liabilities and stockholders’ equity	$ 586,350	$ 642,837

About Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO- 316, an allogeneic CAR T cell product candidates for the treatment of immune checkpoint inhibitor; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

CEO	Dr. David D. Chang M.D., Ph.D.
WEBSITE	allogene.com
INDUSTRY	Biotechnology
EMPLOYEES	359

Allogene Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Allogene Therapeutics Inc? What does ALLO stand for in stocks?

ALLO is the stock ticker symbol of Allogene Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Allogene Therapeutics Inc (ALLO)?

As of Mon May 13 2024, market cap of Allogene Therapeutics Inc is 495.47 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALLO stock?

You can check ALLO's fair value in chart for subscribers.

What is the fair value of ALLO stock?

You can check ALLO's fair value in chart for subscribers. The fair value of Allogene Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Allogene Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALLO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Allogene Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ALLO is over valued or under valued. Whether Allogene Therapeutics Inc is cheap or expensive depends on the assumptions which impact Allogene Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALLO.

What is Allogene Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, ALLO's PE ratio (Price to Earnings) is -1.7 and Price to Sales (PS) ratio is 5.7 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALLO PE ratio will change depending on the future growth rate expectations of investors.